Program
Adjuvanted RZV vaccine
Its studies are mostly in Cardiovascular Diseases, led by GlaxoSmithKline.
Furthest: phase 2, since Jul 14, 20261 company-led study, 1 open or runningNext primary completion: May 2, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 2since Jul 14, 2026 | Jul 14, 2026 | May 2, 2029phase 2 · NCT07712380 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2026First study: phase 2 study in Cardiovascular DiseasesFirst studyNCT07712380 · 450 planned
Ahead
- May 2, 2029Primary completion: phase 2 study in Cardiovascular DiseasesNCT07712380
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Adjuvanted RZV vaccine”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07712380Cardiovascular Diseases | 2 | Not yet recruiting | May 2, 2029 | 450 |
How it is read
Names in the registry
- “Adjuvanted RZV vaccine”, 1 entry
Conditions, from the studies’ own filings
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.